University of Campania Luigi Vanvitelli   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Caserta Italy (1991)

Organization Overview

First Clinical Trial
1999
NCT00490958
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

A.O.U. dell'Università degli studi della Campania "Luigi Vanvitelli" | Azienda Ospedaliera dei Colli | Chair of cardiology Second University of Naples | Department of Geriatrics and Metabolic Diseases, Second University of Naples, Italy | Department of Psychiatry - University of Campania "Luigi Vanvitelli" | Gaetano Isola, DDS, PhD | Second University Naples | Second University of Naples, Italy; Chair Medical Oncology | Second University of Naples, Italy; Chair Medical Statistics | Second University of Naples, Italy; Chair of Medical Statistics | Second University of Naples Medical School | Second Univesity of Naples | Second Univesity of Naples, Italy | Second Univesity of Naples, Italy; Chair Medical Oncology | Serafino A. Marsico | Unit of Endocrinology and Metabolic Diseases University of Campania Luigi Vanvitelli | università degli studi della campania Luigi Vanvitelli | Università della Campania L Vanvitelli | University of Campania "Luigi Vanvitelli"

Active Ingredients

Drugs in Phase 4 Trials (40)

acetylcarnitine (1 trial)

acetylsalicylic acid (aspirin) (1 trial)

aliskiren (tekturna) (2 trials)

alpha-lipoic acid (1 trial)

amlodipine (norvasc) (1 trial)

atenolol (tenormin) (1 trial)

autologous cardiac stem cells (1 trial)

bevacizumab (avastin) (5 trials)

canagliflozin (invokana) (2 trials)

carboplatin (paraplatin) (7 trials)

carvedilol (coreg) (1 trial)

clonidine (catapres) (1 trial)

dapagliflozin (farxiga) (1 trial)

doxazosin (cardura) (1 trial)

empagliflozin (jardiance) (1 trial)

epoetin (Epogen) (1 trial)

fenofibrate (fenoglide) (2 trials)

furosemide (lasix) (2 trials)

glimepiride (amaryl) (2 trials)

horse chestnut (1 trial)

hydrochlorothiazide (esidrix) (1 trial)

incretin (2 trials)

ingenol mebutate (picato) (1 trial)

insulin degludec (tresiba) (1 trial)

insulin glargine (toujeo) (2 trials)

insulin human (humulin) (7 trials)

insulin lispro (humalog) (1 trial)

irbesartan (avapro) (1 trial)

ivabradine (corlanor) (3 trials)

levosimendan (1 trial)

liraglutide (victoza) (2 trials)

lixisenatide (adlyxin) (1 trial)

paclitaxel (taxol) (8 trials)

pioglitazone (actos) (2 trials)

ramipril (altace) (1 trial)

rosuvastatin (crestor) (1 trial)

simvastatin (zocor) (1 trial)

sitagliptin (januvia) (2 trials)

telmisartan (micardis) (1 trial)

vildagliptin (2 trials)

Drugs in Phase 3 Trials (35)

bifidobacterium animalis (1 trial)

capecitabine (xeloda) (1 trial)

cisplatin (platinol) (7 trials)

colistin (1 trial)

dacarbazine (dtic-dome) (1 trial)

docetaxel (taxotere) (2 trials)

doxorubicin (Doxil) (2 trials)

erlotinib (tarceva) (1 trial)

esomeprazole (nexium) (1 trial)

etoposide (vepesid) (1 trial)

fotemustine (1 trial)

futuximab (1 trial)

gemcitabine (gemzar) (10 trials)

glutathione (1 trial)

gluten (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

letrozole (femara) (1 trial)

levofloxacin (levaquin) (1 trial)

modotuximab (1 trial)

oryza sativa (1 trial)

pemetrexed (alimta) (2 trials)

procaine benzylpenicillin (novocaine) (1 trial)

resveratrol (1 trial)

reuterin (1 trial)

rifampin (1 trial)

sodium chloride (1 trial)

sorafenib (nexavar) (1 trial)

tamoxifen (nolvadex) (1 trial)

tinidazole (tindamax) (1 trial)

tipiracil (lonsurf) (2 trials)

topotecan (hycamtin) (1 trial)

trifluridine (viroptic) (2 trials)

triptorelin (Trelstar) (1 trial)

vinorelbine (navelbine) (3 trials)

zoledronic acid (zometa) (1 trial)

Drugs in Phase 2 Trials (19)

avelumab (bavencio) (3 trials)

cetuximab (erbitux) (5 trials)

colchicine (colbenemid) (1 trial)

durvalumab (imfinzi) (1 trial)

exemestane (aromasin) (1 trial)

fluorouracil (efudex) (2 trials)

galunisertib (1 trial)

gefitinib (iressa) (1 trial)

irinotecan (Camptosar) (1 trial)

lapatinib (tykerb) (1 trial)

leucovorin (2 trials)

levoleucovorin (fusilev) (1 trial)

ly3200882 (1 trial)

neridronic acid (1 trial)

oxaliplatin (eloxatin) (2 trials)

panitumumab (vectibix) (2 trials)

pazopanib (votrient) (1 trial)

pembrolizumab (keytruda) (1 trial)

tremelimumab (Imjudo) (1 trial)

Drugs in Phase 1 Trials (1)

ranibizumab (lucentis) (1 trial)

Drugs in Other Trials (6)

arginine (1 trial)

ketamine (ketalar) (1 trial)

lactobacillus reuteri (1 trial)

lidocaine (xylocaine) (1 trial)

vitamin d3 (1 trial)

warfarin (coumadin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Angioid Streaks (Phase 1)

Asthma (Phase 3)

Autonomic Nervous System Diseases (Phase 4)

beta-Thalassemia (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 4)

Cardiomyopathies (Phase 4)

Choroidal Neovascularization (Phase 1)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Communicable Diseases (Phase 3)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Cystic Fibrosis (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Nephropathies (Phase 4)

Diabetic Retinopathy (Phase 4)

Endometrial Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Fibrosis (Phase 4)

Foot Ulcer (Phase 4)

Healthcare-Associated Pneumonia (Phase 3)

Heart Diseases (Phase 4)

Heart Failure (Phase 4)

Helicobacter Infections (Phase 3)

Hyperlipidemias (Phase 4)

Hyperlipoproteinemias (Phase 4)

Hypersensitivity (Phase 3)

Hypertension (Phase 4)

Hypoglycemia (Phase 4)

Infarction (Phase 4)

Infections (Phase 3)

Intraabdominal Infections (Phase 3)

Ischemia (Phase 4)

Keratosis (Phase 4)

Keratosis, Actinic (Phase 4)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Lung Neoplasms (Phase 3)

Melanoma (Phase 3)

Motor Neuron Disease (Phase 2)

Myocardial Infarction (Phase 4)

Myocardial Ischemia (Phase 4)

Myopia (Phase 1)

Myopia, Degenerative (Phase 1)

Neovascularization, Pathologic (Phase 1)

Nervous System Diseases (Phase 4)

Osteoporosis (Phase 2)

Ovarian Neoplasms (Phase 4)

Pancreatic Neoplasms (Phase 3)

Pneumonia (Phase 3)

Pneumonia, Ventilator-Associated (Phase 3)

Recurrence (Phase 3)

Renal Insufficiency, Chronic (Phase 4)

Retinal Diseases (Phase 4)

Rhinitis (Phase 3)

Rhinitis, Allergic (Phase 3)

Rhinitis, Allergic, Seasonal (Phase 3)

Sclerosis (Phase 2)

Small Cell Lung Carcinoma (Phase 3)

Tachycardia (Phase 4)

Takotsubo Cardiomyopathy (Phase 4)

Thalassemia (Phase 2)

Ulcer (Phase 4)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 77
  • # of Trial APIs: 101